Growth • Penumbra
PEN
Domiciled in the US, Penumbra designs, manufactures, and markets an array of thrombectomy and embolization devices and equipment to mechanically remove blood clots. The firm sells mainly to hospitals and physicians. These minimally invasive devices are primarily used in the acute care setting for patients with stroke, pulmonary embolism, deep vein thrombosis, cranial aneurysms, and other vascular diseases.
16,9%
CAGR Revenue 5Y
Revenue Compound Annual Growth Rate in the last 5 years.
12,7%
CAGR Op. Income 5Y
Operating Income Compound Annual Growth Rate in the last 5 years.
-22%
CAGR Net Income 5Y
Net Income Compound Annual Growth Rate in the last 5 years.
-23,1%
CAGR EPS 5Y
Earnings Per Share Compound Annual Growth Rate in the last 5 years.
4,6%
CAGR Normalized EPS 5Y
Normalized Earnings Per Share Compound Annual Growth Rate in the last 5 years.
44,6%
CAGR OCF 5Y
Cash Flow from Operating activities Compound Annual Growth Rate in the last 5 years.
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!